Le Lézard
Classified in: Health
Subjects: PDT, TRI, FDA

MagVenture Inc: FDA Clears new Non-pharmaceutical Device for the Treatment of Depression


ATLANTA, May 8, 2017 /PRNewswire/ --

Atlanta-based company MagVenture Inc. can now add another FDA cleared medical device to its product portfolio. The technology behind is Transcranial Magnetic Stimulation, also known as TMS. It is indicated for the treatment of major depressive disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode .

"The new FDA cleared MagVita TMS Therapy® system is tailormade for healthcare professionals seeking an entry-level TMS system without having to compromise on quality and safety," says MagVenture Inc. VP of Sales, Kerry Rome. Kerry Rome further emphasizes that the company will continue to provide the same high level of technical expertise and dedicated support it is known and respected for.

The MagVita TMS Therapy system first received FDA clearance for the treatment of major depressive disorder in 2015 and many healthcare professionals across the US now offer MagVita TMS Therapy in their practice. The new FDA cleared device from MagVenture caters specifically to smaller psychiatric practices, wishing to start up as a TMS provider but unsure of the patient flow.

"The device, which is also CE marked in Europe, has proven to be a popular choice among clinicians in many countries across the world. Additionally, more and more insurance companies now cover TMS for depression, and this solution will enable even more clinics to get on board and start to offer TMS for the treatment of depression," ends Kerry Rome.

What is TMS?

Transcranial Magnetic Stimulation, or TMS, is an effective, non-invasive alternative for the large number of patients not responding to medication. It does not require anesthesia - and is not to be confused with ECT (Electro Convulsive Therapy).

The MagVita TMS Therapy system delivers magnetic pulses to stimulate nerve cells in the part of the brain controlling the mood. The rapid change in the magnetic field induces a current, and if the current induced is of sufficient amplitude and duration, it will excite neurons.

MagVenture is a medical device company, based in Denmark, and established in 2007. MagVenture specializes in non-invasive magnetic stimulation systems for depression treatment as well as research within neurophysiology, neurology, cognitive neuroscience, rehabilitation, and psychiatry.

MagVenture's product line of magnetic stimulators is sold under the brand name MagPro. The company sells its products through subsidiaries in the US as well as Germany, and through a network of distributors in Europe, Asia, Middle East, and the Americas.

MagVenture, Inc.
2300 Lakeview Parkway, Suite 700
Alpharetta, GA 30009
USA
Phone: +1-888-624-7764
Email: [email protected]

MagVenture A/S
Lucernemarken 15
3520 Farum
Denmark
Phone: +45-4499-8444
[email protected]

Further information:
Kerry Rome, Vice President Sales, MagVenture Inc., USA: +1-310-213-2697 / [email protected], http://www.magventure.com

SOURCE MagVenture Inc


These press releases may also interest you

at 02:48
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

at 02:00
Amwins Global Risks is delighted to announce Classic Cars and Cotswolds, an auction to raise money for the Matthew Wilson Multiple Myeloma Fund at Blood Cancer UK. The online auction opens today and features Ferraris, Aston Martins, a Rolls Royce, a...

at 01:35
Regulatory News: Sensorion (FR0012596468 ? ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces...



News published on and distributed by: